Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ERASOTCMKTS:FSDDFNASDAQ:FULCNASDAQ:OLMA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeERASErasca$1.42-2.4%$1.29$1.01▼$3.45$400.85M1.121.74 million shs4.01 million shsFSDDFFSD Pharma$12.58+7.2%$8.02$3.43▼$68.66$95.36MN/A11,100 shs197,731 shsFULCFulcrum Therapeutics$6.86-3.0%$4.32$2.32▼$10.13$370.30M2.29969,209 shs396,070 shsOLMAOlema Pharmaceuticals$5.32+0.4%$4.43$2.86▼$16.62$364M2.03856,410 shs361,610 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceERASErasca+31.82%+19.83%+1.40%+5.84%-39.83%FSDDFFSD Pharma+1.47%-4.55%+65.82%+137.65%+3,302.90%FULCFulcrum Therapeutics+2.46%+15.52%+93.70%+96.94%-9.01%OLMAOlema Pharmaceuticals+6.85%+2.71%+5.16%+21.28%-45.08%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationERASErasca3.7218 of 5 stars4.51.00.00.04.02.51.3FSDDFFSD PharmaN/AN/AN/AN/AN/AN/AN/AN/AFULCFulcrum Therapeutics0.5552 of 5 stars1.31.00.00.02.62.50.0OLMAOlema Pharmaceuticals2.185 of 5 stars3.51.00.00.03.52.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceERASErasca 3.00Buy$4.57223.07% UpsideFSDDFFSD Pharma 0.00N/AN/AN/AFULCFulcrum Therapeutics 2.50Moderate Buy$6.29-8.37% DownsideOLMAOlema Pharmaceuticals 3.00Buy$24.50360.53% UpsideCurrent Analyst Ratings BreakdownLatest FSDDF, FULC, ERAS, and OLMA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/29/2025FULCFulcrum TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$6.00 ➝ $9.005/23/2025FULCFulcrum TherapeuticsLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Strong-Buy5/23/2025FULCFulcrum TherapeuticsLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform$4.00 ➝ $12.005/15/2025FULCFulcrum TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Overweight$10.005/14/2025ERASErascaGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$3.005/14/2025OLMAOlema PharmaceuticalsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$20.00 ➝ $18.005/14/2025OLMAOlema PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$25.00 ➝ $22.004/30/2025ERASErascaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $6.004/28/2025OLMAOlema PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.00 ➝ $30.003/28/2025OLMAOlema PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$30.00 ➝ $28.003/26/2025ERASErascaRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$5.00(Data available from 5/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookERASErascaN/AN/AN/AN/A$2.10 per shareN/AFSDDFFSD Pharma$70K1,362.23N/AN/AN/A∞FULCFulcrum Therapeutics$80M4.63N/AN/A$3.80 per share1.81OLMAOlema PharmaceuticalsN/AN/AN/AN/A$4.61 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateERASErasca-$125.04M-$0.62N/AN/AN/AN/A-42.26%-34.97%8/11/2025 (Estimated)FSDDFFSD Pharma-$17.52MN/A0.00∞N/AN/AN/AN/AN/AFULCFulcrum Therapeutics-$97.33M-$0.07N/AN/AN/AN/A-7.31%-6.74%7/30/2025 (Estimated)OLMAOlema Pharmaceuticals-$96.65M-$2.01N/AN/AN/AN/A-53.56%-47.86%8/5/2025 (Estimated)Latest FSDDF, FULC, ERAS, and OLMA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025ERASErasca-$0.12-$0.11+$0.01-$0.11N/AN/A5/13/2025Q1 2025OLMAOlema Pharmaceuticals-$0.49-$0.36+$0.13-$0.36N/AN/A5/1/2025Q1 2025FULCFulcrum Therapeutics-$0.29-$0.28+$0.01-$0.28N/AN/A3/20/2025Q4 2024ERASErasca-$0.12-$0.11+$0.01-$0.11N/AN/A3/18/2025Q4 2024OLMAOlema Pharmaceuticals-$0.63-$0.51+$0.12-$0.51N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthERASErascaN/AN/AN/AN/AN/AFSDDFFSD PharmaN/AN/AN/AN/AN/AFULCFulcrum TherapeuticsN/AN/AN/AN/AN/AOLMAOlema PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioERASErascaN/A11.0011.00FSDDFFSD PharmaN/A1.811.60FULCFulcrum TherapeuticsN/A18.4418.44OLMAOlema PharmaceuticalsN/A7.107.10Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipERASErasca67.78%FSDDFFSD Pharma0.43%FULCFulcrum Therapeutics89.83%OLMAOlema Pharmaceuticals91.78%Insider OwnershipCompanyInsider OwnershipERASErasca14.40%FSDDFFSD PharmaN/AFULCFulcrum Therapeutics7.00%OLMAOlema Pharmaceuticals19.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableERASErasca120283.29 million221.94 millionOptionableFSDDFFSD Pharma107.58 millionN/ANot OptionableFULCFulcrum Therapeutics10053.98 million51.73 millionOptionableOLMAOlema Pharmaceuticals7068.42 million46.18 millionOptionableFSDDF, FULC, ERAS, and OLMA HeadlinesRecent News About These CompaniesH.C. Wainwright Backs Olema Pharmaceuticals (OLMA) as Phase 3 Trials AdvanceMay 30 at 7:16 PM | msn.comOlema Pharmaceuticals Selects 90 mg Palazestrant Dose for Phase 3 OPERA-01 and OPERA-02 TrialsMay 29 at 11:41 PM | nasdaq.comOlema Pharmaceuticals, Inc. (NASDAQ:OLMA) Shares Purchased by Millennium Management LLCMay 29 at 3:39 AM | marketbeat.comBank of America Corp DE Increases Stock Position in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)May 29 at 3:21 AM | marketbeat.comOlema Oncology Announces Palazestrant Dose Selection and Trial-in-Progress Poster at ASCO 2025 Annual MeetingMay 28 at 7:00 AM | globenewswire.comBNP Paribas Financial Markets Makes New $1.13 Million Investment in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)May 23, 2025 | marketbeat.comOlema Oncology to Participate in Upcoming Investor ConferencesMay 21, 2025 | globenewswire.comWall Street Analysts See a 386.42% Upside in Olema Pharmaceuticals (OLMA): Can the Stock Really Move This High?May 21, 2025 | zacks.comOlema Pharmaceuticals, Inc. (NASDAQ:OLMA) Shares Acquired by MPM Bioimpact LLCMay 16, 2025 | marketbeat.comParadigm Biocapital Advisors LP Buys 1,801,370 Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)May 16, 2025 | marketbeat.comLightspeed Management Company L.L.C. Makes New Investment in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)May 14, 2025 | marketbeat.comOlema Oncology Reports First Quarter 2025 Financial and Operating ResultsMay 13, 2025 | globenewswire.comDriehaus Capital Management LLC Takes Position in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)May 13, 2025 | marketbeat.comWhat Role Might (NASDAQ:OLMA) Play in the Changing Landscape of the...May 12, 2025 | kalkinemedia.comBalyasny Asset Management L.P. Buys 418,492 Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)May 12, 2025 | marketbeat.comOlema Oncology to Participate in Upcoming Investor ConferencesMay 9, 2025 | globenewswire.comOlema Pharmaceuticals (OLMA) Projected to Post Earnings on WednesdayMay 9, 2025 | marketbeat.comDeep Track Capital LP Sells 557,167 Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)May 9, 2025 | marketbeat.comWhy Olema Pharmaceuticals, Inc.’s (OLMA) Stock Is Down 5.94%May 6, 2025 | aaii.comBVF Inc. IL Sells 3,420,000 Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)May 6, 2025 | marketbeat.comBoxer Capital Management LLC Invests $3.79 Million in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)May 4, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeFSDDF, FULC, ERAS, and OLMA Company DescriptionsErasca NASDAQ:ERAS$1.42 -0.04 (-2.41%) Closing price 04:00 PM EasternExtended Trading$1.40 -0.02 (-1.06%) As of 06:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.FSD Pharma OTCMKTS:FSDDF$12.58 +0.84 (+7.16%) As of 05/29/2025FSD Pharma, Inc. is a specialty biotech pharmaceutical research and development company. It focuses on developing over time a robust pipeline of FDA-approved synthetic compounds targeting the endocannabinoid system of the human body to treat certain diseases of the central nervous system and autoimmune disorders of the skin, GI tract, and the musculoskeletal system. The company was founded by Thomas Fairfull, Zeeshan Saeed and Anthony J. Durkacz in 1994 and is headquartered in Cobourg, Canada.Fulcrum Therapeutics NASDAQ:FULC$6.86 -0.21 (-2.97%) Closing price 04:00 PM EasternExtended Trading$6.87 +0.01 (+0.15%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Olema Pharmaceuticals NASDAQ:OLMA$5.32 +0.02 (+0.38%) Closing price 04:00 PM EasternExtended Trading$5.26 -0.06 (-1.03%) As of 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock Finding Upside With NVIDIA's Blackwell Ackman Takes a Swing at Amazon — Should You? Taiwan Semiconductor: Time to Buy After Strong NVIDIA Results? Intel’s Turnaround May Be the Best Bet No One’s Watching Nike’s Amazon Expansion Could Signal a Turnaround in 2025 ASML Stock Might Be the Safest Chip Play at This Price Archer Aviation Stock Steadies After Short-Seller Report e.l.f. Beauty Sees Record Surge After Earnings, Rhode Deal Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
